Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-based optimization of PKCtheta inhibitors.

L Mosyak1, Z Xu, D Joseph-McCarthy

  • 1Chemical and Screening Sciences, Wyeth Research, Cambridge, MA 02140, U.S.A. lmosyak@wyeth.com

Biochemical Society Transactions
|October 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complete Genome Sequencing Reveals Unusual Equine Rotavirus A of Bat Origin from India.

Journal of virology·2022
Same author

Subperiosteal inferior maxillectomy in mucormycosis patients: case series.

The Journal of laryngology and otology·2021
Same author

Diagnosis of osteoarticular tuberculosis by immuno-PCR assay based on mycobacterial antigen 85 complex detection.

Letters in applied microbiology·2021
Same author

Outcomes of Mechanical Thrombectomy in the Early (<6-hour) and Extended (≥6-hour) Time Window Based Solely on Noncontrast CT and CT Angiography: A Propensity Score-Matched Cohort Study.

AJNR. American journal of neuroradiology·2021
Same author

COPD exacerbation rates are higher in non-smoker patients in India.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

Rhabdomyolysis and acute kidney injury following multiple wasp stings.

QJM : monthly journal of the Association of Physicians·2020
Same journal

TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis.

Biochemical Society transactions·2026
Same journal

Advancing the monitoring of organelle contact sites in vitro and in vivo.

Biochemical Society transactions·2026
Same journal

Mechanisms influencing transient cytoplasmic protein targeting to intracellular lipid droplets.

Biochemical Society transactions·2026
Same journal

Replication associated nuclear DNA mismatch repair across kingdoms.

Biochemical Society transactions·2026
Same journal

Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis.

Biochemical Society transactions·2026
Same journal

Implications of Rho GTPase signaling in cancer immunotherapy.

Biochemical Society transactions·2026
See all related articles

Researchers are developing protein kinase Ctheta (PKCtheta) antagonists to treat diseases like asthma and autoimmune disorders. Small molecules blocking PKCtheta

Area of Science:

  • Immunology
  • Pharmacology
  • Structural Biology

Background:

  • Protein kinase Ctheta (PKCtheta) is a key signaling molecule in T-cell activation.
  • Dysregulation of PKCtheta is implicated in inflammatory and autoimmune diseases.
  • Current drug discovery efforts target PKC inhibitors for cancer, diabetes, and arthritis.

Purpose of the Study:

  • To develop novel PKCtheta antagonists for treating asthma and autoimmune diseases.
  • To identify small-molecule agents that inhibit PKCtheta's catalytic activity.

Main Methods:

  • Discovery of lead chemical series targeting PKCtheta.
  • Application of X-ray crystallography and computational modeling.
  • Utilization of a structure-surrogate strategy for lead optimization.

Related Experiment Videos

Main Results:

  • Identification of promising lead chemical series for PKCtheta antagonism.
  • Structural insights guided the optimization of lead compounds.
  • Demonstrated feasibility of a structure-surrogate approach in drug design.

Conclusions:

  • PKCtheta antagonists represent a viable therapeutic strategy for allergic and autoimmune conditions.
  • Integrated structural and chemical approaches accelerate the discovery of potent inhibitors.
  • The developed methodology facilitates the optimization of small-molecule drug candidates.